Durable response to pembrolizumab in microsatellite instability‐high advanced adrenocortical carcinoma
Masaya Senda,
Kohei Hashimoto,
Tetsuya Shindo
et al.
Abstract:IntroductionAdvanced adrenocortical carcinoma has a poor prognosis and is treated with chemotherapy that includes mitotane with etoposide, doxorubicin, and cisplatin as first‐line therapy. However, second‐line therapy has not been determined yet. Pembrolizumab has been approved for high microsatellite instability for which standard treatments have failed.Case presentationHere, we present a patient with advanced adrenocortical carcinoma treated with complete surgical resection. 21 months later, he had local and… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.